Brief: Hepion Pharmaceuticals Initiates Wind-Down Activities In Phase 2B ‘Ascend-Nash’ Trial
19/04/2024 21:32
April 19 (Reuters) - Hepion Pharmaceuticals Inc
HEPA.O :
* HEPION PHARMACEUTICALS INITIATES WIND-DOWN ACTIVITIES IN
PHASE
2B ‘ASCEND-NASH’ TRIAL
* HEPION PHARMACEUTICALS INC - THERE WERE NO SAFETY CONCERNS
OBSERVED FOR RENCOFILSTAT IN ASCEND-NASH TRIAL
Source text for Eikon: ID:nGNX6w6w54
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement